Profile data is unavailable for this security.
Mergers & acquisitions
| Acquired company | QTTB:NMQ since announced | Transaction value |
|---|---|---|
| Q32 Bio Inc | 69.60% | -- |
Data delayed at least 15 minutes, as of May 10 2024 16:01 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | 38.30m | -134.81m | 301.62m | 123.00 | -- | 10.78 | -- | 7.88 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Verastem Inc | -100.00bn | -100.00bn | 301.67m | 73.00 | -- | 12.04 | -- | -- | -- | -- | -- | 0.9903 | -- | -- | -- | -- | -- | -62.70 | -- | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.6208 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 302.27m | 862.00 | 62.02 | 1.07 | 14.88 | 0.6979 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Procaps Group SA | 414.10m | 52.20m | 311.39m | 5.50k | 5.30 | 7.91 | 4.47 | 0.752 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -192.96m | 315.84m | 79.00 | -- | 1.09 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 319.71m | 7.00 | -- | 1.18 | -- | 276.57 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 323.13m | 45.00 | -- | 3.05 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Precigen Inc | 6.23m | -95.90m | 325.62m | 202.00 | -- | 2.71 | -- | 52.31 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| MeiraGTx Holdings PLC | 14.02m | -84.03m | 327.96m | 419.00 | -- | 2.35 | -- | 23.40 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 328.41m | 40.00 | -- | 2.35 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 329.66m | 158.00 | -- | 0.9603 | -- | 9.87 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 331.00m | 75.00 | -- | 0.5906 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 332.57m | 100.00 | -- | 16.83 | -- | 64.91 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 338.72m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Data as of May 10 2024. Currency figures normalised to Q32 Bio Inc's reporting currency: US Dollar USD
5.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2023 | 313.95k | 2.63% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 106.75k | 0.90% |
| Newtyn Management LLCas of 31 Dec 2023 | 77.74k | 0.65% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 42.85k | 0.36% |
| BML Capital Management LLCas of 31 Mar 2024 | 24.89k | 0.21% |
| Geode Capital Management LLCas of 31 Dec 2023 | 17.97k | 0.15% |
| George Kaiser Family Foundationas of 31 Dec 2023 | 17.03k | 0.14% |
| Adar1 Capital Management LLCas of 31 Dec 2023 | 16.32k | 0.14% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 10.62k | 0.09% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 9.70k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
